ArcherDX Revenue and Competitors

Claim your profile

Boulder, CO USA



Total Funding



Estimated Revenue & Valuation

  • ArcherDX's estimated annual revenue is currently $2.9M per year.(i)
  • ArcherDX received $35.0M in venture funding in March 2018.
  • ArcherDX's estimated revenue per employee is $95,000
  • ArcherDX's total funding is $150M.

Employee Data

  • ArcherDX has 31 Employees.(i)
  • ArcherDX grew their employee count by -24% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types. By combining novel enrichment chemistry, automated informatics and a user-friendly workflow, Archer products remove the bottlenecks associated with using next-gen sequencing in a translational setting.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





ArcherDX News

2022-04-19 - Gene-editing company seeks incentives for large-scale Louisville expansion

... Genapsys Inc. has operations in Westminster; Invitae Corp., a medical-genetics company, acquired Boulder-based ArcherDX in late 2020;...

2022-03-30 - Foresight Diagnostics Announces the Hiring of Sandra Close, Ph.D ...

Close has served as an executive leader in both diagnostic and pharmaceutical companies, including at ArcherDX/Invitae and Eli Lilly, among...

2022-03-22 - Immune Repertoire Sequencing Market Technological ...

... Growth Opportunity and Forecast 2022-2028 | Thermo Fisher Scientific, Inc., Illumina Inc., ArcherDX, Inc., Roche Holding AG,.

2019-12-17 - Boulder Biotech Company Lands $55M for Personalized Genomic Medicine

Boulder's ArcherDX, a biotech company developing personalized genomic medicine, announced it closed a $55 million Series C round to grow its commercial footprint and further its product offerings. The round was led by Perceptive Advisors, which was joined by new investors Redmile Group, Soleus ...

2019-12-17 - ArcherDX Closes $55M Series C Financing

ArcherDX, Inc., a Boulder, Colo.-based molecular diagnostics company dedicated to developing solutions that advance the application of personalized genomic medicine, closed a $55m Series C financing. The round was led by Perceptive Advisors, which was joined by new investors Redmile Group, Sole ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

ArcherDX Funding

DateAmountRoundLead InvestorsReference
2018-03-21$35.0MABoulder Ventures, Ltd.Article